when used in central venous injections for digital subtraction angiography , sodium meglumine ioxaglate ( hexabrix ) has been found to be associated with a high incidence of nausea and vomiting ( 24.5 % ) , when compared with iohexol ( omnipaque ) ( 0 % ) in 101 patients .
C0022005
iohexol
C0729203
omnipaque